Short-Term Effects of Liraglutide and Metformin

If you’re managing PCOS and struggling to lose weight with metformin alone, combining it with liraglutide may be a more effective option. A 12-week study found that obese women with PCOS who added liraglutide to their treatment lost 6.5 kg (14.3 lbs) on average, compared to just 1.2 kg (2.6 lbs) with metformin alone. This combination also improved insulin sensitivity, hormonal balance, and waist circumference.

Key Takeaways:

• Combination Therapy vs. Metformin Alone: Women using both liraglutide and metformin experienced 5x more weight loss than those on metformin alone.
• Hormonal and Metabolic Benefits: Improvements included lower testosterone levels, better glucose control, and reduced insulin resistance.
• Side Effects: Common issues like nausea were manageable with gradual dose increases.

This approach offers a more effective path for weight loss and addressing metabolic and hormonal challenges in PCOS. However, side effects and individual response should be discussed with a healthcare provider.

Clinical Trial Overview

Study Methods and Participant Characteristics

Researchers at the University Medical Center Ljubljana conducted a 12-week study using a prospective, randomized, open-label design to evaluate the effects of combining liraglutide and metformin. This approach allowed for a direct comparison of treatments.

The trial included 40 obese women with PCOS who had been on metformin for at least six months but had not achieved meaningful weight loss (defined as less than 5% of their body weight). These women were considered poor responders to standard treatment. All participants had a BMI of 30 kg/m² or higher and were diagnosed based on the National Institute of Child Health and Human Development (NICHD) criteria. Interestingly, other studies in this area have included women with lower BMI thresholds (≥24 kg/m²) using the Rotterdam criteria.

For the treatment protocol, participants received metformin at 1,000 mg twice daily (totaling 2,000 mg per day). Liraglutide was gradually increased from 0.6 mg daily to a target dose of 1.2 mg to help manage gastrointestinal side effects. Participants were required to use barrier contraception during the study and were excluded if they had diabetes, thyroid disorders, or other hormonal conditions that could interfere with the results.

These carefully structured methods provided a solid foundation for assessing both the primary and secondary outcomes of the treatment.

Study Objectives

The primary aim of the study was to determine whether adding liraglutide could enhance weight loss in women who had not responded adequately to metformin alone. The researchers focused on measuring weight loss and changes in BMI over the 12-week period. A key benchmark for success was achieving a weight reduction of at least 5% of the participants' initial body weight.

Secondary objectives included evaluating changes in metabolic markers (such as fasting blood glucose, HOMA-IR, and cholesterol), hormonal parameters (including testosterone levels, LH/FSH ratios, and SHBG), and reproductive health indicators (like menstrual regularity, ovulation, and spontaneous conception). The study also closely monitored safety, particularly gastrointestinal side effects and episodes of low blood sugar.

"Short-term combined treatment with liraglutide and metformin was associated with significant weight loss and decrease in waist circumference in obese women with PCOS who had previously been poor responders regarding weight reduction on metformin monotherapy." - Mojca Jensterle Sever, Department of Endocrinology, University Medical Center Ljubljana

Micro Video- Use of the New Anti-diabetes Medications in the Treatment of Women with PCOS

Weight Loss and Body Composition Results

Weight Loss and BMI Changes

The study's findings on weight loss and body composition outcomes highlight some notable differences between treatment approaches.

Women who added liraglutide to their metformin regimen experienced an average weight loss of 6.5 ± 2.8 kg (14.3 lbs), compared to just 1.2 ± 1.4 kg (2.6 lbs) for those taking metformin alone. This difference was statistically significant, with a P-value of less than 0.001.

BMI reductions followed a similar pattern. The combination therapy group saw a decrease of 2.4 ± 1.0 kg/m², while the metformin-only group had a reduction of just 0.5 ± 0.5 kg/m². Waist circumference also decreased more significantly in the combination group, shrinking by 5.5 ± 3.8 cm, compared to 1.6 ± 2.9 cm in the metformin-only group.

Additionally, a 22% responder rate (defined as achieving at least 5% weight loss) was observed in the combination therapy group, while no responders were recorded in the metformin-only group.

Results Comparison Table

The table below provides a clear comparison of the weight loss outcomes across the different treatment groups:

Treatment Group	Weight Loss	BMI Reduction	Waist Circumference Reduction	Responder Rate (≥5% Weight Loss)
Metformin (1,000 mg twice daily)	1.2 ± 1.4 kg	0.5 ± 0.5 kg/m²	1.6 ± 2.9 cm	0%
Liraglutide (1.2 mg daily)	3.8 ± 3.7 kg	1.3 ± 1.3 kg/m²	3.2 ± 2.9 cm	16%
Combination Therapy	6.5 ± 2.8 kg	2.4 ± 1.0 kg/m²	5.5 ± 3.8 cm	22%
High-Dose Liraglutide (3.0 mg daily)	6.3 ± 3.7 kg	2.2 ± 1.3 kg/m²	4.2 ± 3.4 cm	57.1%

These results clearly show that adding liraglutide to metformin significantly improves weight loss outcomes, particularly for individuals who respond poorly to metformin alone. The combination therapy proved to be over five times more effective than metformin by itself.

Metabolic and Hormonal Improvements

The combination of liraglutide and metformin brings significant benefits to key metabolic and hormonal markers, proving to be an effective strategy for managing PCOS.

Insulin Sensitivity
A 2025 meta-analysis of 12 randomized controlled trials with 1,096 participants showed that this combination therapy decreased HOMA-IR by 0.82 and fasting insulin levels by 2.21 (P < 0.00001) when compared to metformin alone. Additionally, a 12-week study conducted from January 2021 to January 2022 at Shengjing Hospital of China Medical University involved 52 overweight women with PCOS. Led by Dr. Bing He, the research demonstrated significant reductions in both fasting insulin and HOMA-IR (P < 0.01), highlighting improvements in hormonal regulation. These findings align with the weight loss benefits previously discussed, showcasing the therapy's well-rounded effectiveness.

Glucose Metabolism
The therapy also enhanced glucose metabolism. Participants experienced reductions in fasting blood glucose by 0.95 and 2-hour postprandial glucose by 0.98 compared to those on metformin alone (P < 0.00001).

Hormonal Balance
The combination therapy contributed to notable hormonal improvements. Total testosterone levels dropped from 0.79 to 0.62 ng/mL (P = 0.032), while the Free Androgen Index declined from 12.72% to 7.06% (P = 0.004). Other changes included a reduction in LH levels from 9.77 to 6.61 mIU/mL (P = 0.036), an increase in SHBG from 22.40 to 27.00 nmol/L (P = 0.018), and a rise in progesterone from 0.54 to 1.08 ng/mL (P = 0.020).

"The combination of liraglutide and metformin resulted in greater improvements in body weight, blood sugar levels, insulin sensitivity, hormone balance... and offers more comprehensive metabolic and hormonal benefits than metformin alone for women with PCOS."
– Diabetes, Obesity and Metabolism

Lipid Profiles
Improvements in lipid profiles were also observed. Total cholesterol levels decreased by 2.34, and triglycerides were reduced by 0.58 compared to metformin alone.

These results demonstrate how quickly and effectively liraglutide and metformin can enhance metabolic and hormonal health, delivering measurable benefits within just 12 weeks for women managing PCOS.

sbb-itb-6dba428

Side Effects and Tolerability

Maintaining tolerability is key to ensuring the long-term metabolic benefits seen in short-term studies.

The combination of liraglutide and metformin delivers notable metabolic improvements, but it does come with side effects that patients should be aware of before beginning treatment. Most side effects are mild to moderate and typically subside within the first few weeks. Below is a detailed overview of these effects and strategies to manage them effectively.

The most common side effects are gastrointestinal (GI) issues. A meta-analysis of 12 randomized controlled trials, involving 1,096 patients, revealed that combination therapy led to a higher incidence of GI reactions compared to metformin alone. Frequently reported side effects include nausea (43%–54.5%), diarrhea, headaches (27%), and insomnia (9%–18%). Rarely, patients may experience injection site reactions, while hypoglycemic events remain minimal, showing no significant difference compared to metformin monotherapy.

The severity and duration of these side effects can vary by individual and even by geographic region. For example, studies conducted in China reported an average GI reaction rate of 15%, while non-Chinese studies noted rates closer to 30%. Interestingly, one study highlighted that while patients on liraglutide experienced more nausea than those on metformin alone, the nausea lessened over time and wasn’t linked to the amount of weight loss achieved.

"Gradual dose titration reduced the GI side effects associated with liraglutide."
– Mojca Jensterle Sever, Department of Endocrinology, Diabetes and Metabolic Diseases

Serious side effects were rare in clinical trials. One notable case involved a patient who developed acute cholangitis due to gallstones while on combination therapy, which led to their withdrawal from the study. To reduce the likelihood of side effects, experts recommend starting liraglutide at a low dose of 0.6 mg daily and gradually increasing it to 1.2 mg after one week. This gradual approach helps minimize GI symptoms, which generally resolve within one to four weeks.

Combining low-dose liraglutide (1.2 mg) with metformin has shown better tolerability than using high-dose liraglutide (3 mg) alone. For instance, nausea rates were lower at 43% for the combination therapy compared to 57% for high-dose monotherapy. Properly managing these side effects is crucial for maintaining patient adherence and achieving the best possible metabolic and hormonal outcomes.

Comparison with Other Clinical Studies

The findings from this trial align closely with broader research on combination therapy for managing weight in PCOS patients. For instance, a 2025 meta-analysis of 19 randomized controlled trials involving 1,657 women revealed that combining liraglutide with metformin was more effective than metformin alone in reducing body mass index, fasting blood glucose levels, and insulin resistance. These results echo a broader trend in research, which consistently highlights the advantages of combination therapy across various metabolic and hormonal parameters. Such consistent outcomes warrant a closer look at how combination therapy stacks up against other treatment options in clinical practice.

Recent trials have added more clarity to the weight loss advantages of combination therapy. Studies repeatedly show that combination treatments lead to better weight loss and metabolic improvements. For example, the Frontiers 2025 trial found that 94.12% of participants using combination therapy achieved a clinically significant weight reduction (≥5%), compared to just 52.63% of those on metformin alone. Similarly, research on alternative GLP-1 receptor agonists like Beinaglutide demonstrated that combination therapy resulted in a weight loss of 4.54 kg, compared to 2.47 kg with metformin monotherapy.

When comparing treatment regimens, some notable differences emerge. High-dose liraglutide monotherapy (3 mg) may achieve similar weight loss results, but combination therapy provides additional hormonal benefits, such as improved androgen levels and reduced testosterone. These distinctions emphasize the need for personalized treatment strategies to address both weight management and hormonal imbalances in PCOS patients.

The Frontiers 2025 trial also highlighted the superior impact of combination therapy on hormonal and metabolic markers. It was more effective at lowering free testosterone levels (P = 0.01) and reducing visceral fat area compared to metformin alone. Additionally, a meta-analysis showed significant improvements in lipid profiles, with reductions in total cholesterol and triglycerides (SMD = -2.34 and -0.58, respectively).

Tolerability has been consistent across studies. While gastrointestinal side effects are more common with combination therapy, they do not lead to an increase in hypoglycemic events, as previously discussed.

How Oana Health Supports PCOS Treatment

Oana Health takes the findings from clinical trials and turns them into practical solutions for managing PCOS. By offering telehealth services, the platform provides patients with access to care that incorporates combination therapy proven to be effective. Through virtual consultations with licensed medical professionals, patients receive personalized treatment plans that include medications like liraglutide and metformin, conveniently delivered straight to their homes.

For those who see less than a 5% reduction in body weight using metformin alone - commonly referred to as "poor responders" - liraglutide can be added to enhance results. Treatment plans are tailored to individual needs, whether the focus is on achieving significant weight loss or managing androgen levels. Research shows that high-dose liraglutide (3 mg) is more effective for reducing weight and waist circumference, while combining metformin with low-dose liraglutide (1.2 mg) is better suited for improving androgen profiles and lowering total testosterone levels. This personalized approach ensures both clinical effectiveness and patient convenience.

To reduce side effects like nausea and diarrhea, doses are adjusted gradually. Medications are delivered directly to patients’ homes with free shipping, removing the need for pharmacy visits.

Monthly plans start at $22 and can include metformin, spironolactone, or a combination of GLP-1 and metformin. Oana Health goes beyond just weight management, addressing a range of PCOS symptoms such as insulin resistance, unwanted facial hair, hair thinning, acne, and mental health challenges. This comprehensive care model is rooted in evidence showing that combination therapy can significantly improve hormonal imbalances, including reductions in total testosterone and the free androgen index. For those primarily focused on weight loss, Oana Health also offers a specialized weight loss platform.

Conclusion

Clinical trials have demonstrated that combination therapy offers better short-term results for PCOS patients struggling with weight loss and metabolic issues. Data from 19 randomized controlled trials, involving 1,657 women, show that this approach leads to significantly greater weight loss. Notably, 38% of patients who previously saw minimal results with metformin alone achieved at least a 5% reduction in body weight when combination therapy was used.

These improvements extend beyond weight loss. Patients also saw notable progress in metabolic and hormonal health, including enhanced insulin sensitivity, lower fasting blood glucose levels, and better hormonal balance. Significant reductions in total testosterone and luteinizing hormone levels were also reported.

"The combination of liraglutide and metformin resulted in greater improvements in body weight, blood sugar levels, insulin sensitivity, hormone balance (including LH, FSH and testosterone) and cholesterol profiles."

• PubMed Meta-Analysis

In addition to weight loss, combination therapy positively impacts metabolic and hormonal stability in PCOS patients. Approximately 81.7% of individuals achieved clinically meaningful weight loss - defined as losing more than 5% of their baseline weight - along with improvements in ovulation rates and menstrual regularity. These changes not only enhance key clinical markers but also support better menstrual cycles and fertility outcomes. While gastrointestinal side effects, such as nausea, are more frequent with this treatment, they are usually manageable through gradual dose adjustments and tend to lessen over time.

Oana Health builds on this evidence by offering personalized, science-driven treatment plans. With medical oversight, convenient home delivery, and flexible options, their approach makes effective combination therapy accessible for PCOS patients aiming for targeted weight loss and hormonal balance.

FAQs

What are the short-term benefits of using liraglutide and metformin together for PCOS?

Combining liraglutide with metformin has demonstrated encouraging results for managing PCOS, particularly in the short term. Research highlights notable benefits such as weight loss, improved blood sugar levels, and enhanced metabolic health when compared to using either medication on its own.

Women with PCOS who used this combination saw reductions in body weight, BMI, and metabolic issues, especially in cases involving obesity. This dual approach also shows potential in tackling insulin resistance, a frequent concern for those with PCOS.

How does combining liraglutide and metformin help improve hormonal balance in women with PCOS?

The combination of liraglutide and metformin works to improve hormonal balance in women with PCOS by tackling the underlying metabolic issues that interfere with hormone regulation. This treatment has been shown to aid in weight loss, decrease insulin resistance, and reduce elevated androgen levels - common challenges for individuals with PCOS. These improvements can lead to more regular menstrual cycles and alleviate symptoms such as excessive hair growth and acne.

By boosting insulin sensitivity and addressing high androgen levels, this therapy supports healthier hormonal regulation and may also enhance fertility. Together, liraglutide and metformin address the core metabolic disruptions of PCOS, offering a well-rounded approach to managing symptoms and restoring balance.

What side effects can occur when using liraglutide and metformin together?

When taking liraglutide and metformin together, some side effects may occur. The most commonly reported include:

• Nausea: 7.1%
• Abdominal pain or discomfort: 7.1%
• Diarrhea: 4.8%
• General discomfort: 4.8%
• Itching: 2.4%
• Vomiting: 1.2%
• Constipation: 1.2%

Most of these side effects are mild and tend to go away on their own. However, if they persist or become more severe, it’s important to reach out to a healthcare professional. Always stick to your doctor’s instructions when using these medications together.